Agenix Limited Announces Initial China Sales of Hep B Drug YouHeDing

Published: Jan 04, 2008

January 4, 2007 -- Australian biotech Agenix (ASX: AGX) reported that its new treatment for hepatitis B notched sales of 10 million RMB ($1.4 million) in December, its first month on the market. YouHeDing, as the treatment is known, was approved by the SFDA in October 2007. According to Agenix, YouHeDing (adefovir dipivoxil tablets) has a novel crystalline structure when compared to other approved versions of adefovir dipivoxil. It is the first triclinic structured form of the drug developed and patented in China. More details...

Back to news